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Abstract
Background: In assisted reproductive technology, prediction of treatment failure remains a great challenge. The
development of more sensitive assays for measuring anti-Müllerian hormone (AMH) has allowed for the possibility
to investigate if a lower threshold of AMH can be established predicting very limited or no response to maximal
ovarian stimulation.
Methods: A prospective observational multicenter study of 107 women, < 40 years of age with regular menstrual
cycle and serum AMH levels ≤ 12 pmol/L, treated with 300 IU/day of HP-hMG in a GnRH-antagonist protocol. AMH
was measured before treatment start using the Elecsys® AMH assay by Roche Diagnostics. The ability of AMH to
predict follicular development and ovarian response was assessed by receiver operating characteristics (ROC).
Furthermore, the relationship between AMH at start of stimulation and cycle outcome was investigated using
multivariate logistic regression analysis.
Results: Five out of 107 cycles (4.7%) were cancelled due to lack of follicular development and 60/107 (56%)
women did not reach the classical hCG criteria for ovulation induction (≥ 3 follicles of ≥17 mm). An AMH threshold
of 4 pmol/L predicted failure to reach the classical hCG criteria with 89% specificity and 53% sensitivity and an area
under the curve (AUC) of 0.76 (95% CI 0.66–0.85). AMH predicted cycle cancellation due to lack of follicular
development, using a cut-off value of 1.5 pmol/L, with a specificity of 96% and sensitivity of 80% (AUC = 0.92, 95%
CI 0.79–1.00). A single-unit increase in AMH was associated with a 29% decrease in odds of failure to reach the
classical hCG criteria (OR 0.71 95% CI 0.59–0.85, p < 0.01). The lowest AMH value compatible with a live birth was
1.3 pmol/L.
Conclusions: Among women with a limited ovarian reserve, pre-treatment serum AMH levels significantly
predicted failure to reach the classical hCG triggering criteria and predicted lack of follicular development using a
new sensitive assay, but AMH was not suitable for withholding fertility treatment, as even very low levels were
associated with live births.
Trial registration: Not relevant
Keywords: In vitro fertilization (IVF), Ovarian stimulation, Anti-Müllerian hormone (AMH), Poor ovarian response,
Receiver operating characteristics (ROC) curve analysis
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Background
Anti-Müllerian Hormone (AMH) is a glycoprotein se-
creted from the granulosa cells of preantral and antral
follicles [1], and has shown to be a good predictor of the
response to ovarian stimulation for assisted reproductive
technology (ART) [2]. AMH has therefore gained widely
use in the clinical practice of fertility clinics and is con-
sidered as valid as antral follicle count (AFC), but has
the advantage of less inter observer variability [3].
Poor ovarian reserve affects 5–10% of patients undergo-
ing ART depending on the average female age of the infer-
tile population [4], and is associated with decreased yield
of oocytes, cycle cancellation and a reduced probability of
pregnancy [5]. One of the clinical challenges regarding pa-
tients with poor ovarian reserve is to identify the patients
in whom the ovarian reserve is below the lower threshold
for ovarian stimulation. In other words, to identify those
women with a severely affected ovarian reserve, where
maximal gonadotrophin stimulation will result in less than
3 mature follicles, which define the classical criteria for
triggering of ovulation with hCG, and thus result in cycle
cancellation.
Several different studies have addressed the issue of pre-
dicting outcome in poor prognosis patients [6–10]. How-
ever, various AMH assays and the lack of an international
reference standard for AMH has made it difficult to com-
pare data from different clinical settings. The most exten-
sively used AMH assay is the Beckman-Coulter AMH
Gen II assay. However, concern has been raised regarding
the reliability of the assay as within-subject variability and
complement interference has been documented [11].
Furthermore, the original Beckman-Coulter AMH Gen
II assay could not detect levels of AMH < 3 pmol/L. Pa-
tients with AMH values below the detection level have
demonstrated acceptable live births rates, as assessed
by Seifer et al. in a SART database study of over 5000
cycles reporting of live-birth rate of 9.5% in women
with AMH levels below the detection limit [6]. Thus,
the lower threshold of AMH, where patients will have
no ovarian response, has not yet been established, and
it could be suspected that the true threshold for ovarian
stimulation lies beneath the limit of detection by the
AMH Gen II assay.
New AMH assays have been developed including the
fully automated Elecsys® AMH Immunoassay (Roche
Diagnostics International Ltd) and the picoAMH assay
(Ansh Labs), both of which can detect levels of AMH
< 3 pmol/L [12, 13]. Burks et al. used the picoAMH assay
in a retrospective case-control study (n = 48) aiming to
identify the lower threshold for ovarian stimulation [14].
They found that the assay performed well in predicting
failure to achieve oocyte retrieval, however clinical preg-
nancy was observed in women with very low AMH levels
(1.0 pmol/L). Unlike the Elecsys® assay, the picoAMH
assay is not automated. Furthermore, it was designed for
the detection of very low AMH levels, and thus the stand-
ard curve is centered around very low values (standard
curve range 1–746 pg/mL), resulting in the majority of
samples requiring dilution before utility of the assay [15].
Compared with the AMH Gen II assay, the Elecsys®
AMH assay have demonstrated lower analytical variability
and closer correlation with AFC in the lower range of
AMH values [16, 17]. These differences could be ex-
plained by improved analytical features such as lower limit
of quantification and maximum imprecision as compared
with the AMH Gen II assay [17]. The enhanced perform-
ance in the lower AMH concentration range by the new
assays may enable a better guidance and counsel of
women with weak AMH production. Whether it is pos-
sible to detect a minimum AMH cut-off value for ovarian
stimulation using a more sensitive assay with a lower de-
tection level is unknown. In this study the pre-treatment
AMH levels were measured prospectively in women with
limited ovarian reserve treated in a maximal gonado-
trophin stimulation protocol, to investigate if the use of
the Elecsys® AMH assay with a lower detection thresh-
old than the old assays, can predict failure to reach the
classical criteria for hCG trigger or failure to develop at
least one mature follicle. Thereby improving the coun-
selling of couples regarding their realistic chances of
success in ART.
Materials and methods
Study design and aim
Prospective observational multicenter cohort study per-
formed in three public fertility clinics in Denmark with
the aim of investigating if serum AMH measured with
the new automated Elecsys® AMH assay could predict
failure to reach the classical criteria for hCG trigger or
failure to develop a single mature follicle.
Patients
Women between 18 and 40 years of age and BMI < 35,
who were referred for IVF/ICSI treatment with a regu-
lar menstrual cycle between 24 and 35 days and a
pre-treatment AMH ≤ 12 pmol/L, measured with the
automated Elecsys® AMH assay, were included in the
study from December 2015 to April 2017. All included
women had both ovaries and gave informed consent in
writing. Exclusion criteria were: Endometriosis stage
III-IV, severe comorbidity (i.e. IDDM, NIDDM, gastro-
intestinal, cardiovascular, pulmonary, liver or kidney
diseases), dysregulation of thyroid disease, not Danish
or English speaking, ovarian cyst at start of stimulation,
and previous inclusion in the study.
The AMH cut-off value for inclusion of 12 pmol/L
corresponds to 15 pmol/L measured with the former
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manual ELISA assay (AMH Gen II assay) as values are
expected to be 20% lower when measured with the
Elecsys® AMH assay [17]. The cut-off value was chosen
on the basis of the study by Yates et al. [18] in which a
cut-off of 15 pmol/L, measured with the AMH Gen II
assay, was used to identify women with limited ovarian
reserve.
Clinical protocol and data collection
All were treated in a GnRH-antagonist protocol with a
fixed dose of 300 IE HP-hMG with fixed daily GnRH an-
tagonist 0.25mg/day added from stimulation day 6. Trig-
gering of ovulation by hCG was done when follicles
reached a size ≥17mm, and any patient with at least one
follicle ≥17mm was offered hCG trigger and oocyte re-
trieval. Oocyte retrieval was performed 36 ± 2 h after hCG
administration. Oocytes were fertilised by either in vitro
fertilization (IVF) or intracytoplasmic sperm injection
(ICSI) and embryos were cultured individually according
to standard procedures. Single Day 2 embryo transfer was
performed and, if available, surplus high-quality embryos
were cryopreserved on either Day 2 or 5. A serum hCG
test was performed two weeks after embryo transfer. Clin-
ical pregnancy was confirmed by transvaginal ultrasound
5–6 weeks after embryo transfer. A positive hCG test was
defined as a serum hCG level of more than 5 IU/L two
weeks after embryo transfer, and ongoing pregnancy was
defined as a foetus with foetal heartbeat at gestational
week 7–8.
Data collection was performed at baseline (cycle day
2–3), stimulation day 6, and on day of hCG triggering.
Blood samples were collected, and transvaginal ultrason-
ography was performed on all three occasions. Size and
number of antral follicles at all occasions were regis-
tered. Serum AMH concentrations were measured using
the fully automated Elecsys® AMH assay from Roche
Diagnostics on the Cobas e 601 analyzer in accordance
with the manufacturer protocols. The assays limit of de-
tection was 0.07 pmol/L and limit of quantitation was
0.21 pmol/L.
Outcome measures
The primary endpoint was the lower serum AMH
threshold that best predicted failure to reach the clas-
sical hCG criteria (at least 3 follicles of ≥ 17mm on day
of hCG administration). The secondary endpoints and
outcome variables were AMH cut-off values predicting
cycle cancellation due to lack of follicular development,
embryo transfer, low oocyte yield (≤ 3 oocytes), positive
hCG test as well as ongoing pregnancy and live births.
For analytic purposes, low oocyte yield was defined as
≤3 oocytes, as used in the Bologna criteria for poor ovar-
ian response [19].
Statistical analysis
Continuous data are presented in median and interquar-
tile range (IQR) and categorical data are presented in
frequencies and percentages. Receiver operator charac-
teristic (ROC) curve analyses for AMH and AFC pre-
dicting failure to reach the classical hCG criteria, cycle
cancellation, embryo transfer, low oocyte yield, positive
hCG test and live birth were calculated. Youden’s Index
(sensitivity + specificity − 1) were calculated to identify
the optimal cut-off points, however to provide the most
applicable cut-off values for clinical practice, cut-off
values with high specificity were preferred when asses-
sing failure to reach the classical hCG criteria, cycle
cancellation due to lack of follicular growth, and low oo-
cyte yield, while high sensitivity was preferred when
assessing embryo transfer, positive hCG test and live
birth. ROC curves for AMH and AFC were compared
using χ2-test.
The ability of baseline serum AMH and AFC to pre-
dict failure to reach the classical hCG criteria was fur-
ther evaluated with univariate logistic regression analysis
along with other explanatory parameters: FSH, age, BMI,
cycle length, previous no. of ART cycles, parity and dur-
ation of infertility. A multivariate logistic regression
model was then performed including the explanatory pa-
rameters found to be significantly associated with failure
to reach the classical hCG criteria in the univariate logis-
tic regression analysis.
Sample size calculation was performed prior to initiat-
ing the study. To detect an area under the curve (AUC)
of 0.65 for AMH on predicting failure to reach the clas-
sical hCG criteria, a sample size of 100 patients would
be necessary to achieve at least 80% power with a 5%
one-sided significance level. This was based on the as-
sumption that the proportion of patients failing to reach
the classical hCG criteria was within the range 0.3–0.7,
as would be expected as only patients with AMH ≤ 12
pmol/L were included.
Results
All 107 included women started ovarian stimulation with
hMG (Fig. 1). Patients characteristics are depicted in
Table 1. The median age (IQR) was 36 (34–38) years,
cycle length 26 (24–27) days and AMH 5 (3.3–8.3)
pmol/L. In total sixty women (56% per started cycle) did
not reach the classical hCG triggering criteria of at least
3 follicles ≥ 17mm at the day of hCG administration
and five women (4.7% per started cycle) had their cycle
cancelled due to lack of follicular development (Table 2).
Among the women that failed to reach the classical hCG
criteria, 6 out of 60 (10%) achieved an ongoing preg-
nancy and live birth, compared with 9 out of 47 (19%) in
the group that reached the classical hCG criteria. No cy-
cles were converted from IVF/ICSI to intrauterine
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insemination. None of the participants had their cycle
cancelled or had GnRH agonist triggering due to risk of
ovarian hyperstimulation syndrome (OHSS).
Predicting follicular development
ROC-curves depicting the ability of AMH and AFC to
predict failure to reach the classical hCG criteria are
presented in Fig. 2a and results from the ROC-curve
analysis are presented in Table 3. The AUC was 0.76
(95% confidence interval (CI) 0.66–0.85) for AMH.
There was no statistically significant difference between
the two ROC-curves for AMH and AFC (p = 0.53).
Including both AFC and AMH in the model provided an
AUC of 0.80 (95% CI 0.72–0.89). The optimal AMH
cut-off value was 4.0 pmol/L providing a specificity of
89% and sensitivity of 53% (false positive rate (FPR):
11%, false negative rate (FNR): 47%). Given the preva-
lence of failure to reach the classical hCG criteria in this
population (56%), the positive predictive value at this
cut-off point was 86% (the proportion of positive test
results that were true positive), while the negative pre-
dictive value was 60% (the proportion of negative test re-
sults that were true negative). The lowest serum AMH
level observed among women who did reach the clas-
sical hCG criteria was 1.30 pmol/L.
Univariate and multivariate logistic regression analysis
of explanatory parameters in predicting failure to reach
the classical hCG criteria are presented in Table 4. Besides
AMH, AFC, age, cycle length, and number of previous
ART cycles were statistically associated with failure to
reach the classical hCG criteria. When adding these pa-
rameters to a multivariate logistic regression model, a
single-unit increase in AMH was associated with a 29%
Fig. 1 Flow-chart of included patients
Table 1 Patient demographics, fertility characteristics and baseline
endocrinology
Demographics Median (IQR) or n (%)
Age, years 36 (34–38)
BMI, kg/m2 22.9 (20.4–25.6)
Cycle length, days 26 (24–27)
Smoking, n (%) 8 (7.4%)
Fertility characteristics
Duration of infertility, months 24 (18–36)
1. ART cycle, n (%) 75 (70)
2. ART cycle, n (%) 17 (16)
3. ART cycle, n (%) 13 (12)
> 3. ART cycle, n (%) 2 (2)
Etiology of infertility, n (%)
Anovulation 2 (2%)
Tubal factor 16 (15%)
Endometriosis 4 (4%)
Male factor 42 (40%)
Unexplained 25 (24%)
Other 33 (31%)
Baseline endocrinology and ultrasound (cycle day 2–3)
AMH, pmol/L 5.0 (3.3–8.3)
FSH, IU/L 10.0 (8.0–13.2)
Progesterone, nmol/L 1.3 (1.0–2.0)
Estradiol, nmol/L 0.12 (0.09–0.17)
AFC, no. of follicles 8 (5–11)
Continuous variables are presented in median (interquartile range (IQR)), and
categorical data are presented in number of occurrence (frequencies
in percent)
BMI body mass index, ART assisted reproductive technologies, AMH anti-
Müllerian hormone, FSH follicle stimulating hormone, AFC antral follicle count
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decrease in odds of failing to reach the criteria (adjusted
odds ratio (aOR) 0.71, 95% CI 0.59–0.85, p = 0.0001).
AMH and AFC both performed well in predicting
cycle cancellation due to lack of follicular development
with an AUC of 0.92 (95% CI 0.86–1.00) and 0.92 (95%
CI 0.86–0.99), respectively (Fig. 2b and Table 3). A
serum AMH cut-off value of 1.5 pmol/L predicted cycle
cancellation with a specificity of 96% and a sensitivity
of 80%.
Predicting embryo transfer and oocyte yield
As presented in Table 2, of the 107 women that
started ovarian stimulation, 102 (95%) had oocyte re-
trieval and 70 (65% per started cycle) had an embryo
transfer. Fifty-seven women (55% per oocyte retrieval)
had 3 or less oocytes retrieved, defining low oocyte
yield. AMH predicted low oocyte yield with an AUC
of 0.81 (95% CI 0.73–0.89), while AFC provided a
statistically significant smaller AUC of 0.68 (95% CI
0.57–0.78), p = 0.004 (Fig. 2c and Table 3). Adding
both AMH and AFC to the model did not increase the
predictive value compared with AMH alone. The opti-
mal AMH cut-off value predicting low oocyte yield
was 4.0 pmol/L (specificity: 88% and sensitivity: 54%).
Both AMH and AFC modestly predicted embryo
transfer (Fig. 2d and Table 3).
Positive hCG test, ongoing pregnancy, and live birth
Twenty-six women out of 107 (24%) had a positive serum
hCG test two weeks after embryo transfer resulting in 15
(14% per started cycle) ongoing pregnancies of which all
resulted in a live birth (Table 2). Among women with an
AMH level < 4 pmol/L only two out of 35 (5.7%) had an
ongoing pregnancy and live birth compared with 13 out of
72 (18%) among women with AMH levels ≥4 pmol/L. The
lowest AMH value among women with a positive hCG
test was 0.98 pmol/L, and 1.3 pmol/L among women that
had a live birth. The results from the ROC curves for the
prediction of a positive hCG test and live birth are pre-
sented in Fig. 2e +F and Table 3. Both AMH and AFC dis-
played poor predictive value for pregnancy and live birth,
though AMH appeared to perform better than AFC with
an AUC = 0.66 (95% CI 0.50–0.82, p = 0.047) for predict-
ing live birth. Only when combining AMH and AFC could
the tests predict live birth with an AUC of 0.70 (95% CI
0.55–0.85, p = 0.01). By univariate logistic regression ana-
lysis serum AMH concentrations were marginally posi-
tively associated with live birth with an OR of 1.21 (95%
CI 1.01–1.46, p = 0.04).
Discussion
The availability of new automated AMH assays have
opened for a theoretical opportunity to identify the
lower AMH threshold for ovarian stimulation. Ideally, a
test of ovarian reserve would be able to predict live
birth, and to identify those patients that have very
limited or no chance of a live birth. These patients
might instead opt for oocyte donation avoiding expen-
sive futile IVF attempts. Patients with undetectable
AMH levels below the limit of the former AMH Gen II
assay have been shown to have acceptable livebirths
rates, indicating that the true lower threshold for ovar-
ian stimulation is below the lower limit of detection
[14]. In this study, we assessed the ability of AMH mea-
sured with the new Elecsys® AMH assay to predict failure
to reach the classical criteria for hCG triggering (at least 3
follicles of > 17mm at day of hCG administration) and to
predict cycle cancellation due to complete lack of follicu-
lar development during maximal ovarian stimulation for
IVF/ICSI.
Our data suggests that an AMH cut-off value of 4
pmol/L predicts failure to reach the classical criteria for
hCG triggering with a specificity of 89% (FPR of 11%),
and a sensitivity of 53% (FNR of 47%). Hence, among
women with AMH < 4 pmol/L, approximately 9 out of
10 would not reach the classical hCG criteria. The low
sensitivity and high FNR indicates that almost half of the
women not reaching the classical hCG criteria had
AMH ≥ 4 pmol/L. However, when establishing the lower
AMH threshold for ovarian stimulation, a cut-off value
associated with a low FPR (high specificity) would be
Table 2 Cycle characteristics and outcome after ovarian
stimulation and IVF/ICSI
Per started cycle
(n = 107)
Cycles with ovarian stimulation, n (%) 107 (100%)
Stimulation days, median (IQR) 8 (7–10)
Cycles cancelled, n (%) 5 (4.7%)
Cycles reaching the classical hCG
criteria, n (%)
47 (44%)
Oocyte retrieval, n (%) 102 (95%)
No. of oocytes retrieved, median (IQR) 2 (2–3)
Fertilization rate in %, median (IQR) 66.7 (41–100)
Embryo transfer, n (%) 70 (65%)
Embryo cryopreservation, n (%) 28 (26%)
Positive hCG test, n (%) 26 (24%)
Ongoing pregnancy, n (%) 15 (14%)
Live birth, n (%) 15 (14%)
Per embryo transfer
(n = 70)
Positive hCG test, n (%) 26 (37%)
Ongoing pregnancy, n (%) 15 (21%)
Live birth, n (%) 15 (21%)
IQR interquartile range, IVF in vitro fertilization, ICSI intracytoplasmic sperm
injection, hCG human chorionic gonadotropin
Grynnerup et al. Reproductive Biology and Endocrinology           (2019) 17:11 Page 5 of 9
preferred, even if this would imply a reduced sensitivity,
as the results may have wide implications for couples
starting ART. In this dataset, a threshold of 4 pmol/L
also appeared to provide the best prognostic value for
predicting low oocyte yield (≤ 3 oocytes), embryo trans-
fer, pregnancy and live birth. The live birth rate per cycle
among women with pre-treatment AMH < 4 pmol/L was
lower compared to women with AMH ≥ 4 pmol/l, how-
ever this did not reach statistical significance (5.7% vs
18%, p = 0.08) probably due to sample size. Even though
one baseline AMH measurement does not seem suffi-
cient for withholding IVF/ICSI, as also levels below this
cut-off value were compatible with a live birth, the
cut-off value of AMH < 4 pmol/L does offer some prog-
nostic value in a population of women with limited ovar-
ian reserve to counsel couples that the chance of
livebirth rate will be less than 10% per cycle. Still, the
presented cut-off value, should be externally validated
on a different dataset to confirm the obtained sensitivity
and specificity. Failure to reach the classical hCG criteria
was not significantly associated with a lower live birth
rate compared with women that did reach the criteria
(10% vs 19%, p = 0.17). Thus, failure to reach the clas-
sical hCG criteria might not be the best indicator of
treatment failure.
No international consensus exists for defining a specific
criterium for hCG administration. One of the reasons for
a lack of standard, is that the criteria for ovulation induc-
tion depend on the population studied. In numerous large
international multicenter studies, using either the long
agonist [20] or antagonist [21, 22] protocol in the “stand-
ard” IVF population, the criterium for hCG administration
has been 3 follicles of 17mm or above. Still, lower criteria
for hCG administration have been used in studies specific-
ally dealing with patients predicted to have a low or mod-
erate follicular response. Kolibianakis et al. used 2 follicles
of 17mm or above [23], and in the large international
ESPART study hCG could be used for triggering when at
least one mature follicle was seen on ultrasound [24]. In
our study we investigated the chance of achieving the
traditional cut-off of 3 mature follicles, but on the other
hand we accepted to administer hCG and do retrieval
even with 1 or 2 follicles. The rationale for this is that na-
tional data-sets show an increase in pregnancy rates for
A B
C D
E F
Fig. 2 Receiver Operating Characteristic (ROC) curves for anti-Müllerian hormone (AMH) and antral follicle count (AFC) for predicting a) Failure to
reach the classical hCG criteria; b) Cycle cancellation; c) Low oocyte yield (≤ 3 oocytes); d) Embryo transfer; e) positive hCG test; f) Live birth
Grynnerup et al. Reproductive Biology and Endocrinology           (2019) 17:11 Page 6 of 9
each additional oocyte from 1 to 3 [25], and as we used
maximal stimulation doses of hMG, it was unlikely that a
cancellation due to inadequate response would subse-
quently be improved in another cycle, so we pursued oo-
cyte retrieval even with a single mature follicle.
For the prediction of total lack of follicular development
(cycle cancellation), we found that an AMH cut-off value
of 1.5 pmol/L provided a high specificity and sensitivity
and thus this represents an interesting finding. However,
the cut-off value was based on a limited number of pa-
tients (n = 5) and is therefore not robust enough to apply
in a clinical setting but warrants further studies. It should
also be noted that live birth occurred in one patient with
an AMH level of 1.3 pmol/L.
Both AMH and AFC performed equally in predicting
failure to reach the classical hCG criteria, cycle
cancellation, positive hCG test and live birth. In this
dataset, only in the case of predicting poor oocyte
yield did AMH perform statistically better than AFC. A
meta-analysis from 2013 by Broer et al. (n= 5705) found
similar predictive value of AMH and AFC for poor response
(defined as oocyte yield < 4 or cycle cancellation) and com-
bining the two tests did not improve the predictive value
[3]. However, in concordance with our findings Arce et al.
showed that AMH had a stronger correlation with oocyte
yield compared with AFC (n = 749) [26]. These conflicting
findings may be due to considerable inter-observer variation
in AFC measurements [27], which is one of the major
limitations of AFC for prediction of ovarian response,
particularly in multicentre trials [28, 29]. This may also be
due to the fact that the doctor is more prone to make an op-
timistic AFC measurement while doing the ultrasound scan.
The main limitation of this study is the sample size
which limits the statistical power especially for total lack
of follicular development and live birth associations.
Furthermore, patients that had undergone previous cycle
attempts were also included in this study. Number of pre-
vious ART cycles were included in the logistic regression
analysis which demonstrated that increasing number of
previous ART cycles reduced the risk of failing to reach
Table 3 Receiver operator characteristics curve analysis
AUC 95% CI p-value* Optimal cut-off value Sensitivity Specificity
Failure to reach classical hCG criteria (n = 60)
AMH 0.76a 0.66-0.85 < 0.001 4.0 pmol/L 53% 89%
AFC 0.79a 0.70-0.88 < 0.001 7 63% 78%
Model AFC & AMH 0.80a 0.72–0.89 < 0.001
Cycle cancellation (n = 5)
AMH 0.92a 0.80-1.00 < 0.001 1.5 pmol/L 80% 96%
AFC 0.92a 0.86-0.99 < 0.001 4 60% 91%
Model AFC & AMH 0.95a 0.86–1.00 < 0.001
Low oocyte yield (n = 57)
AMH 0.81b 0.73-0.89 < 0.001 4.0 pmol/L 54% 88%
AFC 0.68b 0.57-0.78 < 0.001 5 38% 88%
Model AFC & AMH 0.81b 0.71–0.88 < 0.001
Embryo transfer (n = 70)
AMH 0.66a 0.55-0.77 0.005 4.2 pmol/L 72% 46%
AFC 0.63a 0.51-0.74 0.030 6 83% 41%
Model AFC & AMH 0.65a 0.54–0.76 0.009
Positive hCG test (n = 26)
AMH 0.60a 0.46-0.73 0.154 4.4 pmol/L 73% 40%
AFC 0.50a 0.36-0.63 0.952 6 73% 25%
Model AFC & AMH 0.61a 0.48–0.75 0.087
Live birth (n = 15)
AMH 0.66a 0.50-0.82 0.047 3.8 pmol/L 93% 31%
AFC 0.53a 0.36-0.70 0.750 6 80% 26%
Model AFC & AMH 0.70a 0.55–0.85 0.008
AUC: area under the curve; CI: confidence interval; AMH: anti-Müllerian hormone; AFC: antral follicle count
*Null-hypothesis: true AUC = 0.5
aNo statistically significant difference between AFC and AMH ROC-curves
bStatistical significant difference between AFC and AMH ROC-curves p = 0.004
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the classical hCG criteria. This most likely reflects a selec-
tion process. Number of previous ART cycles were in-
cluded in the multivariate logistic regression analysis, in
which it did not appear to affect the association between
AMH and failure to reach the classical hCG criteria.
The strengths of the study are the use of the new automated
Elecsys® AMH assay, the prospective design and a selected
population of women with limited ovarian reserve treated
with the same fixed high dose gonadotrophin protocol.
In conclusion, an AMH cut-off value of 4 pmol/L can
predict the development of less than three mature folli-
cles and low oocyte yield with a FPR of only 11 and
12%, respectively. The live birth rate for women with
AMH < 4 pmol/L was 5.7% per started cycle. Thus, one
baseline measurement of AMH is not suitable for ex-
cluding patients from IVF treatment, even when using
a new sensitive assay. Based on our results counselling
can be improved as couples with AMH levels below 4
pmol/L should consider how many futile IVF attempts
they will accept before opting for oocyte donation.
However, studies with repeated AMH measurements
over consecutive cycles and cumulative live birth rates
over a full treatment course in women with very low levels
of AMH measured with the new AMH assays are needed.
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